Tag: Xphyto
-
Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test
Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early pre-symptomatic and asymptomatic stages of infection
-
Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy.
-
XPhyto (XPHY.C) advances a COVID-screener that works like a pregnancy test
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto.
-
Xphyto (XPHY.C) just unlocked a pipeline of biosensor screening projects
Our early coverage of Xphyto reveals the following company trait: Xphyto says, “We’re going to do this” – and then they do it – quickly.
-
Xphyto (XPHY.C) advances delivery system for Parkinson’s drug
Vektor is now proceeding with process implementation for the manufacture of Rotigotine patches for human clinical studies.
-
The real reason for XPhyto’s (XPHY.C) freaky gravity-defying chart
XPHY owns a German narcotic manufacturer called Vektor Pharma, another subsidiary called Bunker that has all the licenses to study cannabis as a medicine, and it has formed multiple partnerships with universities and research centers.
-
Xphyto (XPHY.C) blowing the weed sector out of the water with true 2.0 plan
Xphyto (XPHY.C) is dominating the cannabis sector like Sean Kemp used to dominate the Seattle buffet scene. It’s a legit beast right now, jumping from fat new high to fat new high. We’ve sat with their team several times over the past year and on each occasion have been impressed with their plans, but perhaps…